市場調査レポート

商品コード

がん抗体併用療法の世界市場：市場機会と治験の分析 (2028年)

Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028

出版日: 2023年12月01日 | 発行: KuicK Research

| ページ情報: 英文 1500 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 6,000 940,560円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは出来ません。 PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi-User License)

USD 8,400 1,316,784円

レポートPDFを貴社内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートの分析結果とその概略は、以下の通りとなっています：

世界のがん抗体併用療法の市場機会：2028年までに400億米ドル以上に達する
承認・上市済みのがん抗体併用療法の市場に関する分析：65種類以上の抗体の併用療法
臨床試験中のがん抗体併用療法に関する洞察：450種類以上の抗体の併用療法
承認済み併用療法の特許・価格・投薬量に関する洞察
世界のがん抗体併用療法の治験の分析：企業別、適応症別、相別 (フェーズ別)
世界の抗体併用療法市場の動向：地域別、適応症別

分析に含まれる組み合わせ

承認済み抗体と抗体の併用療法
承認済み抗体と低分子阻害剤の併用療法
承認済み抗体と免疫調節薬の併用療法
承認済み抗体と化学療法の併用療法
承認済み抗体と混合療法
現在進行中の治験：二重特異性抗体、がんワクチン、細胞療法、放射線療法との併用療法

がん治療薬の分野では近年、抗体併用療法の出現によってパラダイムシフトが生じています。これは、特定の分子を標的とする抗体の精度と、各種抗体の相乗効果を組み合わせたダイナミックなアプローチです。種類の異なるモノクローナル抗体を他の治療薬と組み合わせることで、がんの発症に関与する多くの経路を同時に標的とすることができ、それによって相加的あるいは相乗的な効果が得られる可能性があります。理論的には、抗体の併用療法は、薬物動態学的 (PK) 相互作用の欠如とともに、重複する毒性を制限するのに役立つという事実があるため、抗体の併用は、がんの治療法に採用できる非常に適したアプローチです。

抗体と他の治療薬との併用という仮説は1990年代後半に、研究者と科学者が共同で、がん悪性腫瘍で観察される薬剤耐性株の発生やエスケープメカニズムに対処するために、モノクローナル抗体 (mAb) と化学療法、放射線療法、その他の治療薬との併用を含む前臨床試験を強化したことから始まっています。これらの研究の主な目的は、mAbの治療指標と可能性を拡大することです。前臨床試験では、抗体の組み合わせによって、治療効率の向上、毒性の減少、治療や薬剤耐性の発現遅延、さらに投与量の減少といった利点が観察されました。

化学療法や放射線療法のような従来の治療法は、健康な細胞を損傷する可能性をはらんでいましたが、抗体併用療法の登場により、標的医療の状況は一変しました。現在、フェスゴ、ハーセプチンとパージェタ、ラムシルマブとドセタキセル、アテゾリズマブ、ベバシズマブと化学療法、アテゾリズマブとベバシズマブ、イピリムマブとニボルマブなど複数の抗体併用療法が、多様ながんの治療薬としてFDA、EMA、NICEなどから承認されています。

がん治療の領域では、抗体併用療法の領域における予備的臨床開発は、抗PD-1、抗CTLA-4、抗PD-L1モノクローナル抗体 (mAb) 併用療法の創出に焦点が当てられていた、進行性固形がんや血液がんなどの複数のがんに対する第一選択治療として、化学療法や血管内皮増殖因子受容体 (VEGFR) や血小板由来増殖因子受容体 (PDGFR) の様々な経口低分子マルチキナーゼ阻害剤との併用によるmAbの可能性の活用において、最新の改善が観察されています。中国に拠点を置く浙江大学は、抗PD-1抗体とマルチキナーゼ阻害剤ドナフェニブとの併用による治療レジメンの安全性と有効性を評価する臨床試験を実施中です。

中国に拠点を置くもう一つの製薬会社であるChia Tai Tianqing Pharmaceutical Groupは、肝細胞がん (HCC) 患者を対象とした抗PD-1抗体ペンプリマブとマルチ標的受容体TKIアンロチニブの併用療法について報告しました。本試験の主な目的は、術後補助療法としての併用療法の有効性を評価することです。本試験は無作為化二重盲検プラセボ対照多施設共同第3相試験であり、2023年5月に開始され、2026年12月までに完了する予定です。

これまで、がん治療における抗体併用療法の臨床パイプラインは、主にCTLA-4、PD-1、PD-L1などの免疫チェックポイント阻害剤、PP2A阻害剤、CDK4/6阻害剤、HER 2を標的とするmAbs、TIGIT mAbs、二重特異性抗体、CAR-T細胞療法、抗体・薬物併用薬などで構成されています。製薬業界における関心の高まりや、新規併用療法に対するFDA指定の促進から明らかなように、近い将来、がん悪性腫瘍治療のための革新的な抗体併用療法が確実に示されることが予想されます。例えば、2023年8月、アジェナスは、大腸がん患者の治療薬として、革新的な抗体の組み合わせであるボテンシリマブ (AGEN1181) とバルスチリマブ (AGEN2034) のファスト・トラック指定を受けました。

憂慮すべき速さでがんの種類が増加していることから、世界中のがんに苦しむ人々の間で、治療に加えて予期せぬ事態をもたらすことができる、より優れた革新的な抗体併用療法を開発する必要性が高まっています。さらに、Pfizer、Bristol-Myers Squibb、AstraZeneca、Daiichi Sankyo、Agenus、Novartis、Celldex Therapeutics、Merckといった製薬会社やバイオテクノロジー企業など、さまざまな利害関係者が関与することで、抗体併用療法の領域を活用する傾向が強まっています。現在の市場シナリオでは、抗体医薬の組み合わせ市場の将来は有望であり、臨床試験の増加、研究開発の活発化、様々な利害関係者がこの分野に関与していることから明らかなように、さらに拡大すると予想されます。

AbbVie
Adagene
Agenus
Akeso Biopharma
Amgen
AstraZeneca
BeiGene
Biocad
BioInvent International
Bio-Thera Solutions
Boehringer Ingelheim
Bristol-Myers Squibb
Concentra Biosciences
Daiichi Sankyo Company
Eli Lilly and Company
Eucure Biopharma
Genentech
Genmab
GSK
ImmunoGen
Innovent Biologics
Janssen Research & Development
Jiangsu Hengrui Medicine Co.
LaNova Medicines Limited
Lepu Biopharma
MacroGenics
Merck
Merus
NGM Biopharmaceuticals
Novartis
Pfizer
Regeneron Pharmaceuticals
Roche
Seagen
Shanghai Henlius Biotech
Shanghai Junshi Biosciences
Sinocelltech
Symphogen
UCB
Xencor

図表

List of Figures

Figure 1-1: Developmental Milestones for Antibody Combinations
Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination Therapy
Figure 2-2: Need of Antibody Combinations
Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents
Figure 2-4: Expected Antibody Combinations
Figure 3-1: Global - Cancer Antibody Combination Market Opportunity (US$ Billion), 2023 - 2028
Figure 3-2: Antibody Combination Market - Prominent Regions
Figure 3-3: Aspects of Current Antibody Combinations Market
Figure 3-4: Future Characteristics of Antibody Combinations Market
Figure 4-1: COMBI-i Phase III Study - Initiation & Completion Years
Figure 4-2: CONTACT-01 Phase III Study - Initiation & Completion Years
Figure 4-3: NCT05800015 Phase II//III Study - Initiation & Completion Years
Figure 4-4: MagnetisMM-4 Phase II Study - Initiation & Completion Years
Figure 4-5: DREAMM 6 Phase I/II Study - Initiation & Completion Years
Figure 4-6: NCT04421352 Phase I Study - Initiation & Completion Year
Figure 4-7: NCT05867121 Phase I Study - Initiation & Completion Year
Figure 4-8: NCT06054477 Phase I/II Study - Initiation & Completion Year
Figure 4-9: NCT04868877 Phase I/II Study - Initiation & Completion Year
Figure 4-10: NCT05867121 Phase I Study - Initiation & Completion Year
Figure 4-11: NCT06038578 Phase II Study - Initiation & Completion Year
Figure 4-12: DESTINY-Breast01 Phase II Study - Initiation & Completion Year
Figure 4-13: BI-1607 & Trastuzumab Phase I/II Study - Initiation & Completion Year
Figure 4-14: Myechild01 Phase III Study - Initiation & Completion Year
Figure 4-15: GS-9911 & Zimberelimab Phase I Study - Initiation & Completion Year
Figure 4-16: EGIA-002 Phase II Study - Initiation & Completion Year
Figure 4-17: TUC1PI-01 Phase I/II Study - Initiation & Completion Year
Figure 4-18: TUC1PI-01 Phase I/II Study - Initiation & Completion Year
Figure 4-19: LEAP-008 Phase III Study - Initiation & Completion Year
Figure 4-20: VOLGA Phase III Study - Initiation & Completion Year
Figure 4-21: MarkV-01 Phase I Study - Initiation & Completion Year
Figure 5-1: Global - Cancer Antibody Combinations Clinical Trials By Antibody Classification, 2023 till 2028
Figure 5-2: Global - Cancer Antibody Combinations Clinical Trials By Priority Status, 2023 till 2028
Figure 5-3: Global - Cancer Antibody Combinations Clinical Trials By Company, 2023 till 2028
Figure 5-4: Global - Cancer Antibody Combinations Clinical Trials By Country, 2023 till 2028
Figure 5-5: Global - Cancer Antibody Combinations Clinical Trials By Indication, 2023 till 2028
Figure 5-6: Global - Cancer Antibody Combinations Clinical Trials By Phase, 2023 till 2028
Figure 6-1: Lung Cancer - Approved Antibody Combinations
Figure 6-2: Cemiplimab & Fianlimab Phase II/III Study - Initiation & Completion Year
Figure 6-3: Daratumumab, Nivolumab & KRAS vaccine Phase II Study - Initiation & Completion Year
Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations
Figure 6-5: Melanoma - Approved Antibody Combinations
Figure 6-6: NCT05608291 Phase III Study - Initiation & Completion Year
Figure 6-7: OrienX010-II-11 Phase I Study - Initiation & Completion Year
Figure 6-8: MM1636 Phase I/II Study - Initiation & Completion Year
Figure 6-9: Breast Cancer - Approved Antibody Combinations
Figure 6-10: Trastuzumab & Pyrotinib Phase III Study - Initiation & Completion Year
Figure 6-11: Inetetamab, Toripalimab & Paclitaxel Phase IV Study - Initiation & Completion Year
Figure 6-12: Breast Cancer - Key Player in Antibody Combination Commercial Market
Figure 6-13: Breast Cancer - Different Antibody Combination With Other Therapeutic Agents
Figure 6-14: Hepatocellular Cancer- Approved Antibody Combinations
Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular Carcinoma
Figure 6-16: Penpulimab & Anlotinib Phase III Study - Initiation & Completion Year
Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company
Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer
Figure 6-19: NCT06099951 Phase II Study - Initiation & Completion Year
Figure 6-20: KEYFORM-007 Phase III Study - Initiation & Completion Year
Figure 6-21: Renal Cell Carcinoma - Approved Antibody Combinations
Figure 6-22: SillaJen & Regeneron Pharmaceuticals - Novel Approach of Combining Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma
Figure 6-23: BMC128 & Nivolumab Phase I Study - Initiation & Completion Year
Figure 6-24: Lymphoma - Approved Antibody Combinations
Figure 6-25: NCT04464798 Phase I Study - Initiation & Completion Year
Figure 6-26: Odronextamab, Lenalidomide & Rituximab Phase III Study - Initiation & Completion Year
Figure 6-27: L-DEP & PD-1 Antibody Phase III Study - Initiation & Completion Year
Figure 6-28: Collaboration of MorphoSys & Incyte, IGM Bioscience & ADC Therapeutic, 2022
Figure 6-29: Leukemia - Approved Antibody Combinations
Figure 6-30: NCT06043674 Phase II Study - Initiation & Completion Year
Figure 6-31: NP137, Venetoclax & Azacitidine Phase I/II Study - Initiation & Completion Year
Figure 6-32: Novartis - Hypothesis for Phase 3 Clinical Study
Figure 6-33: Sabatolimab & Azacitidine Phase III Study - Initiation & Completion Year
Figure 6-34: Multiple Myeloma - Approved Antibody Combinations
Figure 6-35: NCT05730036 Phase III Study - Initiation & Completion Year
Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple Myeloma
Figure 6-37: NCT05363111 Phase I Study - Initiation & Completion Year
Figure 9-1: Opdivo & Yervoy - Minimum Market Exclusivity Year by Region
Figure 9-2: Opdivo & Yervoy - FDA Approval Years by Indications
Figure 9-3: Opdivo & Yervoy - EMA Approval Years by Indications
Figure 9-4: US - Opdivo Cost per Unit & Supply (US$), December'2023
Figure 9-5: US - Yervoy Cost per Unit & Supply (US$), December'2023
Figure 9-6: EU - Opdivo Cost of Supply (US$), November'2023
Figure 9-7: EU - Yervoy Cost of Supply (US$), November'2023
Figure 9-8: Opdualag - Approval Years by Region
Figure 9-9: Opdualag - Minimum Market Exclusivity Year by Region
Figure 9-10: US & EU - Opdualag Cost per Supply (US$), November'2023
Figure 9-11: Imfinzi & Imjudo - Patent Expiry Years by Region
Figure 9-12: US - Imfinzi Cost per Unit & Supply (US$), November'2023
Figure 9-13: US - Imjudo Cost per Unit & Supply (US$), November'2023
Figure 9-14: EU - Imfinzi Cost per Unit & Supply (US$), November'2023
Figure 9-15: EU - Imjudo Cost per Unit & Supply (US$), November'2023
Figure 9-16: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-17: US - Padcev Cost per Unit & Supply (US$), November'2023
Figure 9-18: EU - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-19: EU - Padcev Cost per Unit & Supply (US$), November'2023
Figure 9-20: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-21: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 9-22: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 9-23: EU - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-24: US - Tecentriq Cost per Unit & Supply (US$), November'2023
Figure 9-25: US - Avastin Cost per Unit & Supply (US$), November'2023
Figure 9-26: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), November'2023
Figure 9-27: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), November'2023
Figure 9-28: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), November'2023
Figure 9-29: EU - Tecentriq Cost per Unit & Supply (US$), November'2023
Figure 9-30: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), November'2023
Figure 9-31: US - Perjeta Cost per Unit & Supply (US$), November'2023
Figure 9-32: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 9-33: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 9-34: EU - Perjeta Cost per Supply (US$), November'2023
Figure 9-35: US - Polivy Cost per Supply (US$), November'2023
Figure 9-36: US - Rituxan Cost per Unit & Supply (US$), November'2023
Figure 9-37: US - Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$), November'2023
Figure 9-38: US - Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$), November'2023
Figure 9-39: EU - Polivy Cost per Supply (US$), November'2023
Figure 9-40: EU - Rituximab Biosimilar Truxima Cost per Supply (US$), November'2023
Figure 10-1: US - Imbruvica Cost per Unit & Supply of 70mg (US$), November'2023
Figure 10-2: US - Imbruvica Cost per Unit & Supply of 140mg (US$), November'2023
Figure 10-3: US - Gazyva Cost per Unit & Supply (US$), November'2023
Figure 10-4: US - Imbruvica Cost per Unit & Supply of 70mg (US$), November'2023
Figure 10-5: US - Imbruvica Cost per Unit & Supply of 140mg (US$), November'2023
Figure 10-6: US - Rituxan Cost per Unit & Supply (US$), November'2023
Figure 10-7: US - Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$), November'2023
Figure 10-8: US - Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$), November'2023
Figure 10-9: EU - Rituximab Biosimilar Truxima Cost per Supply (US$), November'2023
Figure 10-10: US - Bavencio Cost per Unit & Supply (US$), November'2023
Figure 10-11: US - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-12: EU - Bavencio Cost per Unit & Supply (US$), November'2023
Figure 10-13: EU - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-14: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 10-15: US - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-16: EU - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 10-17: EU - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-18: US - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 10-19: US - Tarceva Cost per Supply (US$), December'2023
Figure 10-20: EU - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 10-21: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 10-22: US - Lenvima Cost per Unit & Supply (US$), November'2023
Figure 10-23: EU - Keytruda Cost per Unit & Supply (US$), December'2023
Figure 10-24: US - Opdivo Cost per Unit & Supply (US$), November'2023
Figure 10-25: US - Cabometyx Cost per Unit & Supply (US$), November'2023
Figure 10-26: EU - Opdivo Cost per Unit & Supply (US$), November'2023
Figure 10-27: EU - Cabometyx Cost per Unit & Supply (US$), November'2023
Figure 11-1: US - Monjuvi Cost of Supply (US$), December'2023
Figure 11-2: US - Revlimid Cost per Unit & Supply (US$), December'2023
Figure 11-3: US - Avastin Cost per Unit & Supply (US$), December'2023
Figure 11-4: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), December'2023
Figure 11-5: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), December'2023
Figure 11-6: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), December'2023
Figure 11-7: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December'2023
Figure 12-1: US & EU - Jemperli Cost of Supply (US$), December'2023
Figure 12-2: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-3: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-4: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-5: US - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 12-6: EU - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 12-7: US - Taxotere Cost per Unit & Supply (US$), December'2023
Figure 12-8: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-9: US & EU - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 12-10: US - Gemzar Cost of Supply (US$), December'2023
Figure 12-11: US - Infugem Cost per Unit & Supply (US$), December'2023
Figure 12-12: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-13: US - Vectibix Cost per Unit & Supply (US$), December'2023
Figure 12-14: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 12-15: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 12-16: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-17: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-18: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-19: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-20: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December'2023
Figure 12-21: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US$), December'2023
Figure 12-22: US - Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-23: US - Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$), December'2023
Figure 12-24: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-25: US - Adriamycin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-26: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-27: US - Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-28: US - Vincristine Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-29: US - Toposar Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-30: US - Etoposide Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-31: US - Etoposide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-32: US - Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$), December'2023
Figure 12-33: US - Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$), December'2023
Figure 12-34: US - Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$), December'2023
Figure 12-35: US - Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$), December'2023
Figure 12-36: US - Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$), December'2023
Figure 12-37: US - Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$), December'2023
Figure 12-38: US - Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$), December'2023
Figure 12-39: US - Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$), December'2023
Figure 12-40: US - Vinblastine Cost per Unit & Supply (US$), December'2023
Figure 12-41: US - Dacarbazine Cost per Unit & Supply for 100mg Intravenous Powder (US$), December'2023
Figure 12-42: US - Dacarbazine Cost per Unit & Supply for 200mg Intravenous Powder (US$), December'2023
Figure 12-43: US - Erbitux Cost per Unit & Supply (US$), December'2023
Figure 12-44: US - Camptosar Cost per Unit & Supply (US$), December'2023
Figure 12-45: US - Irinotecan Cost per Unit & Supply (US$), December'2023
Figure 12-46: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-47: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-48: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-49: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-50: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-51: US - Leucovorin Cost of Supply of 100mg, 200mg, 350mg & 500mg Injectable Powder (US$), December'2023
Figure 12-52: US - Leucovorin Cost per Unit & Supply of Injectable Solution (US$), December'2023
Figure 12-53: US - Leucovorin Cost per Unit & Supply of 5mg Oral Tablet (US$), December'2023
Figure 12-54: US - Leucovorin Cost per Unit & Supply of 10mg Oral Tablet (US$), December'2023
Figure 12-55: US - Leucovorin Cost per Unit & Supply of 15mg Oral Tablet (US$), December'2023
Figure 12-56: US - Leucovorin Cost per Unit & Supply of 25mg Oral Tablet (US$), December'2023
Figure 12-57: US - Avastin Cost per Unit & Supply (US$), December'2023
Figure 12-58: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), December'2023
Figure 12-59: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), December'2023
Figure 12-60: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), December'2023
Figure 12-61: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December'2023
Figure 12-62: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-63: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-64: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-65: US - Tecentriq Cost per Unit & Supply (US$), November'2023
Figure 12-66: US - Gemzar Cost of Supply (US$), December'2023
Figure 12-67: US - Infugem Cost per Unit & Supply (US$), December'2023
Figure 12-68: US - Hycamtin Cost of Supply of Oral Capsule (US$), December'2023
Figure 12-69: US - Topotecan Cost of Supply of Intravenous Solution (US$), December'2023
Figure 12-70: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 12-71: EU - Keytruda Cost of Supply (US$), November'2023
Figure 12-72: US - Xeloda Cost per Unit & Supply (US$), November'2023
Figure 12-73: US - Capecitabine Cost per Unit & Supply of 150mg (US$), November'2023
Figure 12-74: US - Capecitabine Cost per Unit & Supply of 500mg (US$), November'2023
Figure 12-75: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-76: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-77: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-78: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December'2023
Figure 12-79: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US$), December'2023
Figure 12-80: US - Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-81: US - Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$), December'2023
Figure 12-82: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-83: US - Adriamycin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-84: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-85: US - Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-86: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-87: US - Abraxane Cost per Unit & Supply (US$), December'2023
Figure 12-88: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-89: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-90: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-91: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 12-92: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 12-93: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-94: US - Gemzar Cost of Supply (US$), December'2023
Figure 12-95: US - Infugem Cost per Unit & Supply (US$), December'2023
Figure 12-96: US - Gemcitabine Cost of Supply of Intravenous Powder for Injection (US$), December'2023
Figure 12-97: US - Gemcitabine Cost per Unit & Supply of 38mg/ml Intravenous Solution (US$), December'2023
Figure 12-98: US - Gemcitabine Cost per Unit & Supply of 100mg/ml Intravenous Solution (US$), December'2023
Figure 12-99: US - Alimta Cost of Supply (US$), December'2023
Figure 12-100: US - Pemfexy Cost per Unit & Supply (US$), December'2023
Figure 12-101: US - Pemetrexed Cost per Unit & Supply of Intravenous Powder for Injection (US$), December'2023
Figure 12-102: US - Pemetrexed Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-103: US - Ellence Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-104: US - Epirubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-105: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 12-106: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 12-107: US - Xeloda Cost per Unit & Supply (US$), November'2023
Figure 12-108: US - Capecitabine Cost per Unit & Supply of 150mg (US$), November'2023
Figure 12-109: US - Capecitabine Cost per Unit & Supply of 500mg (US$), November'2023
Figure 12-110: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-111: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-112: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-113: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml & 500mg/ml (US$), December'2023
Figure 12-114: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US$), December'2023
Figure 12-115: US - Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-116: US - Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$), December'2023
Figure 12-117: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-118: US - Adriamycin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-119: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-120: US - Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-121: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-122: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-123: US - Libtayo Cost per Unit & Supply (US$), December'2023
Figure 12-124: US - Libtayo Cost per Unit & Supply (US$), December'2023
Figure 12-125: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-126: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-127: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-128: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 12-129: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 12-130: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 13-1: US - Phesgo Cost per Unit & Supply (US$), December'2023
Figure 13-2: EU - Phesgo Cost per Unit & Supply (US$), December'2023
Figure 13-3: US - Darzalex Cost per Unit & Supply (US$), November'2023
Figure 13-4: EU - Darzalex Cost per Unit & Supply (US$), December'2023
Figure 13-5: US - Kyprolis Cost per Unit & Supply (US$), November'2023
Figure 13-6: US - Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable Solution (US$), December'2023
Figure 13-7: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable Solution (US$), December'2023
Figure 13-8: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December'2023
Figure 13-9: US - Dexamethasone Cost per Unit & Supply of Oral Liquid (US$), December'2023
Figure 13-10: US - Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg & 6mg Oral Tablets (US$), December'2023
Figure 13-11: US - Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets (US$), December'2023
Figure 13-12: US - Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets (US$), December'2023
Figure 13-13: US - Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets (US$), December'2023
Figure 13-14: US - Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets (US$), December'2023
Figure 13-15: US - TaperDex Cost per Unit & Supply (US$), December'2023
Figure 13-16: US - Velcade Cost per Supply (US$), November'2023
Figure 13-17: US - Bortezomib Cost of Supply (US$), December'2023
Figure 13-18: US - Thalomid Cost per Unit & Supply of 50mg Capsule (US$), December'2023
Figure 13-19: US - Thalomid Cost per Unit & Supply of 100mg & 150mg Capsules (US$), December'2023
Figure 13-20: US - Revlimid Cost per Unit & Supply (US$), December'2023
Figure 13-21: US - Pomalyst Cost per Unit & Supply (US$), December'2023
Figure 13-22: US - Evomela & Generic Melphalan Cost of Supply (US$), December'2023
Figure 13-23: US - Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$), December'2023
Figure 13-24: US - Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$), December'2023
Figure 13-25: US - Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$), December'2023
Figure 13-26: US - Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$), December'2023
Figure 13-27: US - Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$), December'2023
Figure 13-28: US - Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$), December'2023
Figure 13-29: US - Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$), December'2023
Figure 13-30: US - Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$), December'2023
Figure 13-31: US - Empliciti Cost of Supply (US$), November'2023
Figure 13-32: US - Pomalyst Cost per Unit & Supply (US$), December'2023
Figure 13-33: US - Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable Solution (US$), December'2023
Figure 13-34: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable Solution (US$), December'2023
Figure 13-35: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December'2023
Figure 13-36: US - Dexamethasone Cost per Unit & Supply of Oral Liquid (US$), December'2023
Figure 13-37: US - Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg, & 6mg Oral Tablets (US$), December'2023
Figure 13-38: US - Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets (US$), December'2023
Figure 13-39: US - Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets (US$), December'2023
Figure 13-40: US - Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets (US$), December'2023
Figure 13-41: US - Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets (US$), December'2023
Figure 13-42: US - TaperDex Cost per Unit & Supply (US$), December'2023
Figure 13-43: US - Keytruda Cost per Unit & Supply (US$), December'2023
Figure 13-44: EU - Keytruda Cost of Supply (US$), December'2023
Figure 13-45: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 13-46: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 13-47: US - Avastin Cost per Unit & Supply (US$), December'2023
Figure 13-48: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), December'2023
Figure 13-49: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), December'2023
Figure 13-50: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), December'2023
Figure 13-51: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December'2023
Figure 13-52: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 13-53: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 13-54: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 13-55: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 13-56: US - Xeloda Cost per Unit & Supply (US$), November'2023
Figure 13-57: US - Capecitabine Cost per Unit & Supply of 150mg (US$), November'2023
Figure 13-58: US - Capecitabine Cost per Unit & Supply of 500mg (US$), November'2023
Figure 13-59: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 13-60: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 13-61: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 13-62: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 13-63: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 13-64: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 13-65: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 13-66: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 13-67: US - Sarclisa Cost per Unit & Supply (US$), December'2023
Figure 13-68: US - Kyprolis Cost per Unit & Supply (US$), December'2023
Figure 13-69: EU - Sarclisa Cost per Unit & Supply (US$), December'2023
Figure 13-70: US - Pomalyst Cost per Unit & Supply (US$), December'2023

List of Tables

Table 1-1: Global - Approved Cancer Antibody Combinations
Table 9-1: Opdivo & Yervoy Combination - Recommended Dosages
Table 9-2: Imjudo & Imfinzi - Recommended Dosage Schedule for Treatment of NSCLC
Table 10-1: Dose of Gazyva to be Administered During Six 28-Day Treatment Cycles for Patients with CLL
Table 10-2: Cabometyx & Nivolumab - Recommended Dosage of Combination
Table 11-1: Monjuvi - Dosing Schedule
Table 12-1: Jemperli - Recommended Dosage
Table 12-2: US - Approved Cyramza-Chemotherapy Combinations
Table 12-3: US - Approved Vectibix-Chemotherapy Combinations
Table 12-4: US - Approved Adcetris-Chemotherapy Combinations
Table 12-5: Adcetris - Recommended Dosage
Table 12-6: US - Approved Erbitux-Chemotherapy Combinations
Table 12-7: US - Approved Avastin-Chemotherapy Combinations
Table 12-8: US - Approved Keytruda-Chemotherapy Combinations
Table 12-9: Keytruda - Recommended Doses
Table 12-10: US - Approved Herceptin-Chemotherapy Combinations
Table 13-1: Phesgo: Recommended Dosage & Administration Schedule
Table 13-2: US - Approved Darzalex-Chemotherapy Combinations
Table 13-3: Darzalex - Dosing Schedule in Combination with Lenalidomide or Pomalidomide (4-Week Cycle) & Low-Dose Dexamethasone
Table 13-4: Darzalex - Dosing Schedule in Combination with Bortezomib, & Prednisone ([VMP], 6-Week Cycle)
Table 13-5: Darzalex - Dosing Schedule in Combination with Bortezomib, Thalidomide & Dexamethasone ([VTd]; 4-Week Cycle)
Table 13-6: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week Cycle)
Table 13-7: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week Cycle)
Table 13-8: Empliciti - Recommended Dosing Schedule in Combination with Lenalidomide & Dexamethasone
Table 13-9: Empliciti - Recommended Dosing Schedule in Combination with Pomalidomide & Dexamethasone
Table 13-10: US - Approved Keytruda-Chemotherapy Combinations
Table 13-11: Keytruda - Recommended Dosage
Table 13-12: US - Approved Sarclisa-Chemotherapy Combinations
Table 13-13: Sarclisa - Dosing Schedule in Combination with Pomalidomide & Dexamethasone or in Combination with Carfilzomib & Dexamethasone

“Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028” Report Findings & Highlights:

Global Cancer Antibody Combinations Market Opportunity: > USD 40 Billion By 2028
Insight On Approved Cancer Antibody Combinations In Market: > 65 Antibodies Combinations
Insight On Cancer Antibody Combinations In Clinical Trials: > 450 Antibodies Combinations
Patent, Pricing, & Dosage Insight On Approved Combinations
Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase
Global Antibody Combinations Market Development by Region & Indications

Combinations Included In Report:

Approved Antibody - Antibody Combinations
Approved Antibody - Small Molecule Inhibitors Combinations
Approved Antibody - Immunomodulatory Agents Combinations
Approved Antibody - Chemotherapy Combinations
Approved Antibody - Mixed Combinations
Ongoing Clinical Trials Combination With Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Radiotherapy

In recent years, the landscape of cancer therapeutics has witnessed a paradigm shift with the emergence of antibody combination therapies, a dynamic approach that intertwines the precision of antibodies to target specific molecules with the synergistic benefits of different types of antibodies. By merging different types of monoclonal antibodies with other therapeutic agents, numerous pathways that are involved in the pathogenesis of cancer may be targeted simultaneously, thereby, possibly leading to additive or else synergistic effects. Theoretically, the combinations of antibodies are very suitable approach that can be employed for the treatment of cancer modalities because of the fact that the antibody combination therapy aids to limit overlapping toxicity along with lack of pharmacokinetic (PK) interactions.

The hypothesis of combining antibodies with other therapeutic agents began in the late 1990s when the researchers together with scientists amplified the preclinical testing that includes a combinations of monoclonal antibodies (mAb) with chemotherapy, radiotherapy or any other therapeutic agents in order to address the occurrence of drug resistant strains or the escape mechanism for observed in cancer malignancies. The main purpose of these investigations was to expand the therapeutic index as well as the potential of mAbs. Advantages such as amended efficiency, diminished toxicities, delayed development of therapy or drug resistances in addition dose reduction were observed in the preclinical studies that come along with antibody combinations.

In dichotomy with the conventional treatments such as chemotherapy and radiotherapy, which clenches the possibility to damage healthy cells, with the arrival of antibody combination therapies has transformed the landscape of targeted medicine. As of now, multiple antibody combination therapies such as Phesgo, Herceptin with Perjeta, Ramucirumab with docetaxel, atezolizumab, Bevacizumab with chemotherapy, atezolizumab and bevacizumab, and ipilimumab and nivolumab etc have been approved by the FDA, EMA, NICE and others for the treatment of diverse type of cancers.

In the realm of cancer therapy, the preliminary clinical development for the domain of antibody combinations were focused on creating anti-PD-1, anti-CTLA-4 and anti-PD-L1 monoclonal antibody (mAb) combinations, there has been modern improvement observed in harnessing the potential of mAb in conjugation with chemotherapy or with various oral small molecule multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) or platelet derived growth factor receptor (PDGFR) as the first-line treatment for multiple types of cancer like advanced solid tumors, hematological cancer, etc. Zhejiang University based in China is conducting clinical studies in which the combination of anti-PD-1 antibody with Donafenib, multikinase inhibitor, is ongoing to evaluate the safety and efficacy of the treatment regimen.

Another pharmaceutical company based in China, Chia Tai Tianqing Pharmaceutical Group reported another combination of anti-PD-1 antibody, Penpulimab with multi targeted receptor TKI, Anlotinib for the treatment of patients suffering from hepatocellular cancer (HCC). The primary goal of this study is to assess the effectiveness of combined treatment regimen for adjuvant therapy. It is a randomized, double-blind, placebo-controlled, multicenter phase 3 study which was initiated in May 2023 and is expected to be complete by December 2026.

Hitherto, the clinical pipeline for the domain of antibody combination therapy for treating cancer modalities majorly consists of immune checkpoint inhibitors, such as CTLA-4, PD-1 and PD-L1, PP2A inhibitors, CDK4/6 inhibitors, mAbs targeting HER 2, TIGIT mAbs, bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. It is expected that the imminent years will certainly witness innovative antibody combinations for the treatment of cancer malignancies as evident from augmenting interest in pharmaceutical sectors and fostering FDA designations to novel combination therapy. For instance, in August 2023, Agenus was granted the Fast Track Designation for its innovative antibody combination, botensilimab (AGEN1181) and balstilimab (AGEN2034) for the treatment of colorectal cancer patients.

With the increasing prevalence of cancer types at an alarming gait urges the need to develop better as well as innovative antibody combination therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe. Furthermore, an inclining market trend towards utilizing the realm of antibody combination has been observed due to involvement of various stakeholders from pharmaceutical and biotech companies such as Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Agenus, Novartis, Celldex Therapeutics and Merck. With the current market scenario, the future of the antibody combination market looks promising and is expected to multiple further as evident from the growing clinical trials, rising research and development and involvement of various stakeholders in the domain.

1. Introduction to Cancer Antibody Combinations

1.1. History, Development & Evolution
1.2. Approved Cancer Antibody Combinations

2. Need of Antibody Combinations

3. Global Cancer Antibody Combinations Market & Clinical Development Insight

3.1. Current Market Scenario
3.2. Future Outlook

4. Global Antibody Combinations Market Insight by Region

4.1. US
4.2. China
4.3. Europe
4.4. Japan
4.5. UK
4.6. Canada
4.7. South Korea

5. Global Cancer Antibody Combinations Clinical Trials Overview

5.1. By Antibody Classification
5.2. By Breakthrough Therapy & Fast Track Status
5.3. By Company
5.4. By Country
5.5. By Indication
5.6. By Phase

6. Global Antibody Combinations Market Insight by Indication

6.1. Lung Cancer
6.2. Melanoma
6.3. Breast Cancer
6.4. Hepatocellular Cancer
6.5. Colorectal Cancer
6.6. Renal Cell Carcinoma
6.7. Lymphoma
6.8. Leukemia
6.9. Multiple Myeloma

7. Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase

7.1. Research
7.2. Preclinical
7.3. Phase-I
7.4. Phase-I/II
7.5. Phase-II
7.6. Phase-II/III
7.7. Phase-III
7.8. Preregistration
7.9. Registered

8. Approved/Marketed Cancer Antibody Combinations Clinical Trials Insight By Company, Country & Indication

9. Antibody - Antibody Combinations - Pricing, Patent & Dosing Insight

9.1. Opdivo + Yervoy
- 9.1.1. Overview & Patent Insight
- 9.1.2. Pricing & Dosage Insight
9.2. Opdualag (nivolumab & relatlimab)
- 9.2.1. Overview & Patent Insight
- 9.2.2. Pricing & Dosage Insight
9.3. Imjudo + Imfinzi
- 9.3.1. Overview & Patent Insight
- 9.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

10. Antibody - Small Molecule Inhibitors Combinations - Pricing, Patent & Dosing Insight

10.1. Gazyva + Imbruvica
- 10.1.1. Overview & Patent Insight
- 10.1.2. Pricing & Dosage Insight
10.2. Imbruvica + Rituximab
- 10.2.1. Overview & Patent Insight
- 10.2.2. Pricing & Dosage Insight
10.3. Bavencio + Inlyta
- 10.3.1. Overview & Patent Insight
- 10.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

11. Antibody - Immunomodulatory Agents Combinations - Pricing, Patent & Dosing Insight

11.1. Monjuvi + lenalidomide
- 11.1.1. Overview & Patent Insight
- 11.1.2. Pricing & Dosage Insight
11.2. Avastin + Interferon-alfa
- 11.2.1. Overview & Patent Insight
- 11.2.2. Pricing & Dosage Insight

12. Antibody - Chemotherapy Combinations - Pricing, Patent & Dosing Insight

12.1. Jemperli
- 12.1.1. Overview & Patent Insight
- 12.1.2. Pricing & Dosage Insight
12.2. Cyramza
- 12.2.1. Overview & Patent Insight
- 12.2.2. Pricing & Dosage Insight
12.3. Portrazza
- 12.3.1. Overview & Patent Insight
- 12.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

13. Antibody - Mixed Combinations

13.1. Phesgo (Perjeta + Herceptin + hyaluronidase)
- 13.1.1. Overview & Patent Insight
- 13.1.2. Pricing & Dosage Insight
13.2. Darzalex
- 13.2.1. Overview & Patent Insight
- 13.2.2. Pricing & Dosage Insight
13.3. Empliciti
- 13.3.1. Overview & Patent Insight
- 13.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

14. Competitive Landscape

14.1. AbbVie
14.2. Adagene
14.3. Agenus
14.4. Akeso Biopharma
14.5. Amgen
14.6. AstraZeneca
14.7. BeiGene
14.8. Biocad
14.9. BioInvent International
14.10. Bio-Thera Solutions
14.11. Boehringer Ingelheim
14.12. Bristol-Myers Squibb
14.13. Concentra Biosciences
14.14. Daiichi Sankyo Company
14.15. Eli Lilly and Company
14.16. Eucure Biopharma
14.17. Genentech
14.18. Genmab
14.19. GSK
14.20. ImmunoGen
14.21. Innovent Biologics
14.22. Janssen Research & Development
14.23. Jiangsu Hengrui Medicine Co.
14.24. LaNova Medicines Limited
14.25. Lepu Biopharma
14.26. MacroGenics
14.27. Merck
14.28. Merus
14.29. NGM Biopharmaceuticals
14.30. Novartis
14.31. Pfizer
14.32. Regeneron Pharmaceuticals
14.33. Roche
14.34. Seagen
14.35. Shanghai Henlius Biotech
14.36. Shanghai Junshi Biosciences
14.37. Sinocelltech
14.38. Symphogen
14.39. UCB
14.40. Xencor

がん抗体併用療法の世界市場：市場機会と治験の分析 (2028年)

Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028

分析に含まれる組み合わせ

目次

第1章 がん抗体併用療法の概略

第2章 抗体の併用療法の必要性

第3章 世界のがん抗体併用療法の市場・治験の分析

第4章 世界の抗体併用療法市場の分析：地域別

第5章 世界のがん抗体併用療法：治験の概要

第6章 世界の抗体併用療法市場の分析：適応症別

第7章 世界の抗体併用療法の治験の分析：企業別・適応症別・相別

第8章 承認済/上市済みのがん抗体併用療法：治験の考察、企業別・国別・適応症別

第9章 抗体 - 抗体の併用療法：価格・特許・投薬量に関する分析

併用療法の詳細については分析サンプルに記載されています。

第10章 抗体と低分子阻害剤の併用療法：価格・特許・投薬量に関する分析

第11章 抗体と免疫調節剤の併用療法：価格・特許・投薬量に関する分析

第12章 抗体と化学療法の併用療法：価格・特許・投薬量に関する分析

第13章 抗体と他の併用薬の併用療法

第14章 競合情勢

List of Figures

List of Tables

Combinations Included In Report:

Table of Contents

1. Introduction to Cancer Antibody Combinations

2. Need of Antibody Combinations

3. Global Cancer Antibody Combinations Market & Clinical Development Insight

4. Global Antibody Combinations Market Insight by Region

5. Global Cancer Antibody Combinations Clinical Trials Overview

6. Global Antibody Combinations Market Insight by Indication

7. Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase

8. Approved/Marketed Cancer Antibody Combinations Clinical Trials Insight By Company, Country & Indication

9. Antibody - Antibody Combinations - Pricing, Patent & Dosing Insight

Detailed Combinations Are Mentioned in Report Sample.

10. Antibody - Small Molecule Inhibitors Combinations - Pricing, Patent & Dosing Insight

Detailed Combinations Are Mentioned in Report Sample.

11. Antibody - Immunomodulatory Agents Combinations - Pricing, Patent & Dosing Insight

12. Antibody - Chemotherapy Combinations - Pricing, Patent & Dosing Insight

Detailed Combinations Are Mentioned in Report Sample.

13. Antibody - Mixed Combinations

Detailed Combinations Are Mentioned in Report Sample.

14. Competitive Landscape

第1章がん抗体併用療法の概略

第2章抗体の併用療法の必要性

第3章世界のがん抗体併用療法の市場・治験の分析

第4章世界の抗体併用療法市場の分析：地域別

第5章世界のがん抗体併用療法：治験の概要

第6章世界の抗体併用療法市場の分析：適応症別

第7章世界の抗体併用療法の治験の分析：企業別・適応症別・相別

第8章承認済/上市済みのがん抗体併用療法：治験の考察、企業別・国別・適応症別

第9章抗体 - 抗体の併用療法：価格・特許・投薬量に関する分析

第10章抗体と低分子阻害剤の併用療法：価格・特許・投薬量に関する分析

第11章抗体と免疫調節剤の併用療法：価格・特許・投薬量に関する分析

第12章抗体と化学療法の併用療法：価格・特許・投薬量に関する分析

第13章抗体と他の併用薬の併用療法

第14章競合情勢